Core Viewpoint - The comparison between Globus Medical (GMED) and Penumbra (PEN) indicates that GMED presents a better value opportunity for investors at this time due to its more favorable valuation metrics [1]. Valuation Metrics - GMED has a forward P/E ratio of 28.64, while PEN has a significantly higher forward P/E of 87.03 [5]. - The PEG ratio for GMED is 2.03, compared to PEN's PEG ratio of 2.46, suggesting GMED is more reasonably priced relative to its expected earnings growth [5]. - GMED's P/B ratio stands at 2.85, whereas PEN's P/B ratio is much higher at 8.49, indicating that GMED is trading closer to its book value [6]. Earnings Outlook - Both GMED and PEN currently hold a Zacks Rank of 2 (Buy), reflecting an improving earnings outlook supported by positive analyst estimate revisions [3]. - Despite both companies having solid earnings prospects, GMED's valuation metrics suggest it is the superior value option at present [7].

Core Viewpoint - Globus Medical, Inc. has launched the ExcelsiusHub navigation system, enhancing spine navigation safety and efficiency, which is expected to positively influence market sentiment towards GMED stock in the near future [1][4]. Company Developments - The ExcelsiusHub is a significant addition to the Enabling Technologies product category, designed to improve intraoperative navigation for spinal surgeries [2][4]. - The company reported a record number of Excelsius units placed in Q3 2024, indicating strong adoption of its existing technologies [4]. - GMED's market capitalization stands at $11.54 billion, with an average earnings surprise of 17.65% over the last four quarters [5]. Product Features - ExcelsiusHub offers real-time patient array monitoring, tissue-sparing drills, and flexible registration, aimed at reducing reliance on X-ray imaging during surgeries [1][6]. - The system supports various procedures, from minimally invasive to complex spinal surgeries, enhancing operational efficiency and patient safety [8][7]. - It features multiple workflows, including automatic registration with Excelsius3D and intraoperative 2D navigation, providing a comprehensive solution for surgical procedures [7][6]. Market Outlook - The surgical navigation systems market is projected to grow by $2.46 billion by 2030, with a compound annual growth rate of 10.09% from 2022 to 2030, driven by the demand for robot-assisted surgeries and minimally invasive procedures [9]. - GMED's share price has increased by 83.9% over the past year, significantly outperforming the industry average growth of 14.8% [11].

Core Viewpoint - Globus Medical, Inc. has launched the ExcelsiusHub™ navigation system, enhancing its Excelsius™ ecosystem and aiming to improve freehand navigation standards in spine surgery [1][3]. Product Features - ExcelsiusHub™ provides real-time visualization of instrument placement, reducing reliance on X-ray imaging and potentially lowering OR radiation compared to conventional fluoroscopy [2]. - The system includes safety features like patient array shift tracking and navigation of the DuraPro™ Oscillating System, along with imaging versatility through three workflows: automatic registration with Excelsius3D™, CT to fluoroscopy merging, and intraoperative 2D navigation [4]. - It supports a range of procedures from minimally invasive to complex spinal surgeries, enhancing surgical care and optimizing treatment for patients [5]. Market Positioning - The launch of ExcelsiusHub™ is expected to broaden the capabilities of the Excelsius™ ecosystem, catering to diverse needs of surgeons and hospitals, and is designed for both hospital and ambulatory surgical center settings [3]. - The technology aims to facilitate faster and more accurate navigation during surgeries, potentially leading to more efficient operating rooms [5]. Company Overview - Globus Medical, Inc. is a leading global musculoskeletal company focused on addressing unmet clinical needs and advancing care in spine, orthopedic trauma, joint reconstruction, and enabling technologies [6].

Core Insights - Zacks Premium provides various tools for investors to enhance their stock market engagement and confidence [1] - The Zacks Style Scores are designed to complement the Zacks Rank, helping investors identify stocks with the potential to outperform the market in the short term [3][4] Zacks Style Scores - The Style Scores categorize stocks into four types: Value Score, Growth Score, Momentum Score, and VGM Score, each focusing on different investment strategies [4][5][6] - Value Score identifies undervalued stocks using financial ratios like P/E and Price/Sales [4] - Growth Score assesses stocks based on projected earnings and sales growth [5] - Momentum Score evaluates stocks based on price trends and earnings estimate changes [5] - VGM Score combines all three styles to highlight stocks with the best overall characteristics [6] Zacks Rank - The Zacks Rank is a proprietary model that uses earnings estimate revisions to guide investors in stock selection [7] - Stocks rated 1 (Strong Buy) have historically achieved an average annual return of +25.41%, significantly outperforming the S&P 500 [8] - A total of over 800 stocks are rated 1 or 2, making it essential for investors to utilize Style Scores to refine their choices [9] Stock Highlight: Globus Medical (GMED) - Globus Medical, Inc. is a medical device company focused on solutions for musculoskeletal disorders, operating in 51 countries [11] - GMED holds a 2 (Buy) rating on the Zacks Rank and has a VGM Score of A, indicating strong potential [11] - The stock has shown a 9.7% increase over the past four weeks, supported by upward revisions in earnings estimates for fiscal 2024 [12] - The Zacks Consensus Estimate for GMED has risen by $0.11 to $2.95 per share, with an average earnings surprise of 17.7% [12]

Core Viewpoint - Investors are increasingly seeking growth stocks that demonstrate above-average growth potential, with Globus Medical identified as a strong candidate due to its favorable growth metrics and Zacks Rank [1][2]. Earnings Growth - Globus Medical has a historical EPS growth rate of 14.2%, with projected EPS growth of 27.3% for the current year, significantly surpassing the industry average of 17.1% [5]. Cash Flow Growth - The company exhibits a year-over-year cash flow growth of 72.4%, which is notably higher than the industry average of -4.9%. The historical annualized cash flow growth rate over the past 3-5 years stands at 18.2%, compared to the industry average of 5.4% [6][7]. Earnings Estimate Revisions - There has been a positive trend in earnings estimate revisions for Globus Medical, with the Zacks Consensus Estimate for the current year increasing by 4.6% over the past month, contributing to its Zacks Rank of 2 [9]. Investment Positioning - The combination of strong earnings growth, impressive cash flow growth, and favorable earnings estimate revisions positions Globus Medical well for potential outperformance, making it an attractive option for growth investors [10].

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium includes access to the Zacks Style Sc ...

Core Insights - Globus Medical reported a revenue of $625.71 million for the quarter ended September 2024, marking a 63.1% increase year-over-year and exceeding the Zacks Consensus Estimate by 3.44% [1] - The company's EPS for the quarter was $0.83, up from $0.57 in the same quarter last year, representing a surprise of 27.69% over the consensus estimate of $0.65 [1] Revenue Performance - International revenues reached $129.92 million, surpassing the estimated $117.63 million, reflecting a 75% increase compared to the previous year [3] - U.S. revenues totaled $495.79 million, exceeding the average estimate of $483.82 million, with a year-over-year growth of 60.3% [3] Product Category Sales - Net sales from Enabling Technologies were $38.30 million, above the estimated $31.12 million, indicating a 38.5% increase year-over-year [3] - Musculoskeletal Solutions generated $587.40 million in sales, compared to the average estimate of $572.79 million, representing a 69.1% year-over-year growth [3] Stock Performance - Shares of Globus Medical have increased by 6.9% over the past month, contrasting with a -0.5% change in the Zacks S&P 500 composite [4] - The stock holds a Zacks Rank 2 (Buy), suggesting potential outperformance against the broader market in the near term [4]

Globus Medical (GMED) came out with quarterly earnings of $0.83 per share, beating the Zacks Consensus Estimate of $0.65 per share. This compares to earnings of $0.57 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 27.69%. A quarter ago, it was expected that this medical device company would post earnings of $0.68 per share when it actually produced earnings of $0.75, delivering a surprise of 10.29%.Over the last four quarters ...

AUDUBON, Pa., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended September 30, 2024. Worldwide net sales were $625.7 million, an increase of 63.1%GAAP net income for the quarter was $51.8 millionGAAP diluted earnings per share (“EPS”) was $0.38 and non-GAAP diluted EPS was $0.83Non-GAAP adjusted EBITDA was $193.7 million, or 31.0% of net sales “Our third quarter results reflect the endu ...

The upcoming report from Globus Medical (GMED) is expected to reveal quarterly earnings of $0.65 per share, indicating an increase of 14% compared to the year-ago period. Analysts forecast revenues of $604.93 million, representing an increase of 57.7% year over year.Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Prior to a company's earnings announcement ...